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Radiation therapy is a highly technology driven discipline, 
and as treatments become more complex and automated, 
safe implementation and quality assurance become less 
intuitive. Moreover, the discipline seems to face a 
dichotomous situation in that on one hand there is a 
tendency towards truly individualized treatments adapted to 
patient specific characteristics, short or long term variations 
in anatomy and delivered dose, that require flexible 
interventions and optimizations. These individualized 
treatments call for dedicated QA/QC programs. On the other 
hand the automatization in delineation and treatment 
planning in combination with the need to optimize 
workflows, drive development towards template driven, 
almost “app-like” solutions. The latter, seems to facilitate 
workflows and QA/QC procedures in that a strong 
standardization reduces the need for detailed verification. In 
fact, commercial solutions are being offered as “plug-and-
play” with limited user interaction and QA/QC, almost 
ignoring the department’s responsibilities towards patient 
safety and quality. Mix the previous with rapid succession of 
upgrades and updates, and it becomes clear that the 
assessment and QA of technology (still) requires constant 
attention and vigilance. Special care should be given to the 
workflow and how the individual components are integrated 
and mutually influence each other in this constantly evolving 
and increasingly complex situation. The presentation will also 
focus on the discussion between “one shoe fits all” solutions 
versus the need for dedicated technology. Are these 
decisions driven by clinical relevance or a “me-too” 
argumentation? Finally, some comments will be given 
comparing mono-vendor and multi-vendor situations. 
 
Teaching Lecture: CRISPR/CAS technology: from cells to 
mice to stem cell therapy  
 
 
SP-0002  
CRISPR/Cas9 technology: from cells to mice to stem cell 
therapy 
H. Te Riele
1Netherlands Cancer Institute/Antoni van Leeuwenhoek 
Hospital, Division of Biological Stress Response, Amsterdam, 
The Netherlands 
1, T. Harmsen1, H. Van de Vrugt1, J. Riepsaame1 
 
Protocols to efficiently generate small genomic sequence 
alterations in a targeted fashion are of great value to 
fundamental and clinical applications. We are particularly 
interested in developing protocols to correct the genetic 
defects underlying bone marrow failure in Fanconi anemia 
patients.  
The most promising protocols for targeted correction or 
deletion of small mutations in terms of efficiency and facility 
make use of site-specific nucleases designed to generate a 
DNA double-strand break (DSB) in the genomic DNA closely 
located to the site to be modified. The Streptococcus 
pyogenes derived RNA-guided nuclease Cas9 combines strong 
and site-specific endonuclease activity with unprecedented 
design simplicity. By exploiting the endogenous error-free 
homology-directed repair (HDR) pathway that makes use of 
sequence homology, repair of the DSB can be accompanied by 
the introduction of specific base-pair alterations. When a 
double- or single-stranded DNA template is offered, the HDR 
reaction copies subtle sequence alterations present in the 
template sequence effectuating their introduction into the 
genomic DNA. For introduction of small alterations, short 
chemically synthesized single-stranded DNA oligonucleotides 
comprising 80-120 nucleotides are highly effective. We have 
optimized the protocol for single base-pair substitution in the 
genome of mouse embryonic stem (ES) cells by 
oligonucleotide-templated HDR of a CRISPR/Cas9-generated 
break, achieving precise introduction of a planned 
modification in 50% of the recovered cells. Furthermore, we 
studied the influence of the cell’s DNA mismatch repair 
system on the efficiency of gene modification.  
Fanconi anemia (FA) is a recessive heritable disorder 
characterized by skeletal abnormalities, progressive anemia 
and cancer predisposition. The disease is caused by bi-allelic 
defects in any of 17 genes, designated FANCA, B, C, etc. 
When a matching donor is available, bone marrow failure can 
often be treated by hematopoietic stem cell transplantation. 
Also, bone marrow transplantation from a non-matching 
donor can be offered, however, this is often associated with 
severe complications. An alternative strategy to re-establish 
a functional hematopoietic system may be the functional 
correction of the FA defect in the patient’s own cells. 
Ideally, the defect is restored in the patient’s own 
hematopoietic stem cells (HSC), which can subsequently be 
used to reconstitute the entire hematopoietic system. For FA 
patients with insufficient bone marrow cellularity, the FA 
defect may first be corrected in patient-derived primary 
fibroblasts. The corrected fibroblasts subsequently need to 
be reprogrammed into HSCs, most likely requiring the 
generation of induced pluripotent stem cells (iPSCs). As a 
first step towards this approach, we demonstrated that 
CRISPR/Cas9 genome editing can effectively be exploited to 
repair a deleterious mutation in Fancf and restore the FA 
pathway in cultured mouse ES cells and fibroblasts.  
The next step is to use this protocol to correct the Fancf 
mutation in mouse-derived hematopoietic stem cells (HSC) 
and iPSCs. Gene-edited HSCs will subsequently be 
transplanted into lethally-irradiated recipient mice to 
determine their potential to drive long-term hematopoiesis. 
These preclinical studies are aimed to pave the way for the 
clinical development of CRISPR/Cas9-mediated gene 
correction protocols to restore FA gene defects and relieve 
bone marrow failure in Fanconi anemia patients. 
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This lecture will explore the rationale for partial breast 
irradiation and then discuss the results from randomised 
trials to date. These will include intra-operative 
radiotherapy, brachytherapy and external beam 
radiotherapy. There is considerable heterogeneity between 
these techniques in terms of target volume, dose and 
fractionation and possible consequences from these 
differences will be considered. Appropriate patient selection 
for partial breast irradiation and treatment outside clinical 
trials will also be discussed. 
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Radiotherapy plays an important role in the treatment of 
pelvic tumors. The advances in patients’ prognosis come at 
